aTYR PHARMA INC Repayments of Debt
aTYR PHARMA INC (ATYR) reported Repayments of Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2023-03-14
- aTYR PHARMA INC repayments of debt for the quarter ending 2020-12-31 was $3.08M, a 54.15% increase year-over-year.
- aTYR PHARMA INC repayments of debt for the quarter ending 2020-09-30 was $2.00M, a 0.00% change year-over-year.
- aTYR PHARMA INC repayments of debt for the quarter ending 2020-06-30 was $2.00M, a 0.00% change year-over-year.
- aTYR PHARMA INC repayments of debt for the quarter ending 2020-03-31 was $2.00M, a 0.00% change year-over-year.
- aTYR PHARMA INC repayments of debt for fiscal 2022 was $0.00.
- aTYR PHARMA INC repayments of debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- aTYR PHARMA INC repayments of debt for fiscal 2020 was $9.08M, a 13.54% increase from fiscal 2019.
- aTYR PHARMA INC repayments of debt for fiscal 2019 was $8.00M, a 71.42% increase from fiscal 2018.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-14 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 | |||
| 2020-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $5.08M derived: sum of 2 quarters · filed 2023-03-14 | $7.08M derived: sum of 3 quarters · filed 2023-03-14 | $9.08M 10-K · filed 2023-03-14 |
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $4.00M derived: sum of 2 quarters · filed 2021-11-12 | $6.00M 10-Q · filed 2021-11-12 | $8.00M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $4.00M 10-Q · filed 2021-08-11 | $6.00M derived: sum of 3 quarters · filed 2022-03-15 | $8.00M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-14 | $4.00M derived: sum of 2 quarters · filed 2022-03-15 | $6.00M derived: sum of 3 quarters · filed 2022-03-15 | $8.00M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $4.00M derived: sum of 2 quarters · filed 2022-03-15 | $6.00M derived: sum of 3 quarters · filed 2022-03-15 | $8.00M 10-K · filed 2022-03-15 |
| 2019-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $4.00M derived: sum of 2 quarters · filed 2020-11-13 | $6.00M 10-Q · filed 2020-11-13 | $8.00M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $4.00M 10-Q · filed 2020-08-13 | $6.00M derived: sum of 3 quarters · filed 2021-03-24 | $8.00M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | $2.00M 10-Q · filed 2020-05-12 | $4.00M derived: sum of 2 quarters · filed 2021-03-24 | $6.00M derived: sum of 3 quarters · filed 2021-03-24 | |
| 2018-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $4.00M derived: sum of 2 quarters · filed 2021-03-24 | $4.67M 10-K · filed 2021-03-24 | |
| 2018-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $2.67M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $667.00K 10-Q · filed 2019-08-14 | |||
| 2016-12-31 | $5.20M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |